Safety and efficacy outcomes at 1 year after MitraClip therapy for percutaneous mitral valve repair in patients with severe mitral regurgitation: the Egyptian experience

The Egyptian Heart Journal

Table 1 Participants’ demographics

Variables		Total N = 20
Age (years)	Mean ± SD	66.8 ± 10.5
Age (years)	Range	46-84
Gender	Female	3 (15%)
Gender	Male	17 (85%)
BSA (m²)	Mean ± SD	1.77 ± 0.2
BSA (m²)	Range	1.55-2.3
MR etiology	Ischemic	11 (55%)
	Functional	6 (30%)
	Flail	3 (15%)
NYHA class pre	I	0 (0%)
	II	0 (0%)
	III	15 (75%)
	IV	5 (25%)
EuroSCORE	Median (IQR)	11 (9-12.5)
EuroSCORE	Range	7-15
HAS-BLED score	Median (IQR)	1 (1-2)
HAS-BLED score	Range	0-4
Coronary angiography and intervention	Normal CAG	9 (45%)
	TVD for medical treatment	2 (10%)
	LM	1 (5%)
	PCI	7 (35%)
	RCA	5 (25%)
	LAD	4 (20%)
	Non-significant CAD	2 (10%)
	LCX	4 (20%)

N Number, SD Standard deviation, IQR Interquartile range, BSA Body surface area, MR Mitral regurgitation, NYHA New York Heart Association, EuroSCORE European System for Cardiac Operative Risk Evaluation, HAS-BLED Hypertension, abnormal liver/renal function, stroke history, bleeding history or predisposition, labile INR, elderly, drug/alcohol usage, CAG Coronary angiography, TVD Triple-vessel disease, LM Left main coronary artery, PCI Percutaneous coronary intervention, RCA Right coronary artery, LAD Left anterior descending, CAD Coronary artery disease, LCX Left circumflex